Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Beijing Friendship Hospital is the lead sponsor of 64 current clinical trials in our China register. 45 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Tislelizumab, Golidocitinib and Thymalfasin. The most-studied condition is Hypertension.

ClinicalTrials.gov trials by status

Recruiting4570%
Not yet open1219%
Active, closed58%
By invitation23%

Trials by phase

Observational3859%
Not applicable1219%
Phase 269%
Phase 2/335%
Phase 435%
Phase 112%
Phase 1/212%

Clinical trials sponsored by Beijing Friendship Hospital

64 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset NCT07747688 · ClinicalTrials.gov ↗ · Early Gastric Cancer	Observational	Recruiting	2026-05	China
Beijing Friendship Hospital Metabolic Surgery Database NCT03520699 · ClinicalTrials.gov ↗ · Metabolic Surgery	Observational	Recruiting	2017-12	China
BeijngFH Health Cohort Study NCT05546086 · ClinicalTrials.gov ↗ · Non-Alcoholic Fatty Liver Disease	Observational	Recruiting	2022-04	China
PCI in Beijing Friendship Hospital NCT05728580 · ClinicalTrials.gov ↗ · Cardiovascular Diseases, Percutaneous Coronary Intervention	Observational	Recruiting	2017-12	China
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer NCT07315854 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-11	China
A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma NCT05962892 · ClinicalTrials.gov ↗ · Papillary Thyroid Carcinoma, Thermal Ablation	Observational	Recruiting	2024-02	China
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer NCT07353684 · ClinicalTrials.gov ↗ · Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach Drugs: Adebrelimab, Apatinib	Phase 2	Recruiting	2025-05	China
TLSA Versus TBSA Surgical Approach for Hiatal Hernia With Gastroesophageal Reflux Disease NCT07252115 · ClinicalTrials.gov ↗ · Hernia, Hiatal, GERD (Gastroesophageal Reflux Disease)	Not applicable	Recruiting	2024-04	China
Validating a Medical AI Fine-Tuning Platform for Major Diseases NCT07795645 · ClinicalTrials.gov ↗ · Chronic Gastritis, Gastric Cancer (GC), Coronary Artery Disease	Observational	Recruiting	2024-11	China
Comparison Between Prepectoral and Subpectoral Breast Reconstruction NCT05833659 · ClinicalTrials.gov ↗ · Stage II Breast Cancer, Stage I Breast Cancer	Observational	Recruiting	2022-03	China
PBC Long-term Outcomes Study NCT07149675 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC), Long-term Outcomes, Prognosis	Observational	Recruiting	2025-05	China
Prospective Comparative Validation Study of RUCAM and RECAM NCT06771011 · ClinicalTrials.gov ↗ · Drug Induced Liver Injury	Observational	Recruiting	2023-05	China
Golidocitinib Combined With Selinexor for CAEBVD NCT07369739 · ClinicalTrials.gov ↗ · Lymphohistiocytosis, EBV, CAEBV Drugs: Golidocitinib, Selinexor	Phase 2/3	Recruiting	2026-01	China
Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion NCT07611266 · ClinicalTrials.gov ↗ · Colorectal Cancer Control and Prevention	Observational	Recruiting	2025-06	China
Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients NCT06192082 · ClinicalTrials.gov ↗ · Anesthesia	Not applicable	Recruiting	2024-01	China
Non-Invasive Model for Fibrosis Regression in HBV Patients NCT06874127 · ClinicalTrials.gov ↗ · Chronic Hepatitis B Virus (HBV) Infection, Liver Fibrosis	Observational	Recruiting	2024-02	China
Standardized Study Protocol of Percutaneous Vertebroplasty Based on Pedicle Nine-Grid Zoning Method NCT07616583 · ClinicalTrials.gov ↗ · Osteoporotic Vertebral Compression Fractures, Vertebroplasty	Not applicable	Recruiting	2024-01	China
Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance NCT06779864 · ClinicalTrials.gov ↗ · Chronic Hepatitis B	Observational	Recruiting	2024-02	China
Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease NCT06710574 · ClinicalTrials.gov ↗ · Parkinson Disease, Movement Disorders, Rapid Eye Movement Sleep Behavior Disorder	Phase 4	Recruiting	2022-09	China
Prospective Single-Arm Clinical Trial of GO Regimen for HLH. NCT07339345 · ClinicalTrials.gov ↗ · Lymphohistiocytosis, Hemophagocytic Drug: Golidocitinib	Phase 2/3	Recruiting	2025-06	China
Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety NCT07453862 · ClinicalTrials.gov ↗ · Restless Leg Syndrome (RLS), Variant Restless Legs Syndrome	Phase 1	Recruiting	2026-03	China
A Prognostic Model for Drug-induced Liver Injury in China NCT05060289 · ClinicalTrials.gov ↗ · Drug-induced Liver Injury	Observational	Recruiting	2022-05	China
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study NCT05498675 · ClinicalTrials.gov ↗ · Sacubitril/Valsartan, Hypertension, Obesity Drugs: ACEI/ARB, Sacubitril/valsartan	Observational	Recruiting	2021-09	China
China Registry for Genetic / Metabolic Liver Diseases NCT03131427 · ClinicalTrials.gov ↗ · Genetic/Metabolic Liver Diseases	Observational	Recruiting	2015-06	China
Effect of Bariatric Surgery on Cardiac Function in Patients With Hypertension NCT05166954 · ClinicalTrials.gov ↗ · Bariatric Surgery, Hypertension	Observational	Recruiting	2018-08	China
Rivaroxaban in Idiopathic Membranous Nephropathy NCT07404436 · ClinicalTrials.gov ↗ · Idiopathic Membranous Nephropathy	Phase 4	Recruiting	2024-01	China
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" NCT06829355 · ClinicalTrials.gov ↗ · MCRC Drugs: Regorafenib, Thymalfasin, Tislelizumab	Phase 2	Recruiting	2025-02	China
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer NCT06312982 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma Drug: Tislelizumab	Phase 2/3	Recruiting	2024-03	China
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer NCT05245474 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	2022-04	China
Effect of Degenerative Spondylolisthesis on the Clinical Outcome of Unilateral Biportal Endoscopy for Lumbar Spinal Stenosis: Study Protocol NCT06394089 · ClinicalTrials.gov ↗ · Degenerative Spondylolisthesis, Lumbar Spinal Stenosis	Observational	Recruiting	2024-03	China
Effectiveness of Bariatric Surgery for NAFLD/NASH NCT04366999 · ClinicalTrials.gov ↗ · Bariatric Surgery Candidate, NAFLD, NASH With Fibrosis	Observational	Recruiting	2020-04	China
Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer（IDEAL Stage 2b） NCT06788548 · ClinicalTrials.gov ↗ · Early Gastric Cancer	Not applicable	Recruiting	2024-02	China
Chinese Colorectal Cancer Database NCT05434026 · ClinicalTrials.gov ↗ · Colonic Cancer, Rectal Cancer, Prospective Studies	Observational	Recruiting	2022-08	China
The Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal Cancer NCT05015296 · ClinicalTrials.gov ↗ · Colorectal Cancer	Observational	Recruiting	2021-11	China
Opioid Free Anesthesia on the Quality of Early Recovery NCT05577962 · ClinicalTrials.gov ↗ · Opioid-free Anesthesia	Phase 4	Recruiting	2024-08	China
Clinical Indicators and Brain Image Data: a Study Based on Kailuan Cohort NCT05453877 · ClinicalTrials.gov ↗ · Brain Diseases, Hypertension	Observational	Recruiting	2022-08	China
Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy NCT07441850 · ClinicalTrials.gov ↗ · Gastric Cancer	Not applicable	Recruiting	2026-03	China
Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission NCT05015283 · ClinicalTrials.gov ↗ · Type2 Diabetes, Complication of Bariatric Procedure	Not applicable	Recruiting	2022-02	China
Change of Hemodynamics and Cerebral Functions After Carotid Artery Revascularization NCT05539781 · ClinicalTrials.gov ↗ · Carotid Artery Diseases, Carotid Artery Stenosis, Cerebrovascular; Disorder, Arteriosclerotic	Observational	Recruiting	2020-01	China
Eye-Brain-Kidney in CKD NCT07358572 · ClinicalTrials.gov ↗ · Chronic Kidney Diseases	Observational	Recruiting	2025-12	China
Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer NCT07393048 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Observational	Recruiting	2026-02	China
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease NCT03635541 · ClinicalTrials.gov ↗ · Non-Alcoholic Fatty Liver Disease	Observational	Recruiting	2018-08	China
Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome NCT07312864 · ClinicalTrials.gov ↗ · Liver Failure, Small-for-Size Syndrome	Phase 1/2	Recruiting	2025-12	China
A Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset NCT07749989 · ClinicalTrials.gov ↗ · Gastroesophageal Reflux Disease	Observational	Recruiting	2026-04	China
Rectal Cancer Neoadjuvant Therapy-Real World Study NCT07566559 · ClinicalTrials.gov ↗ · Rectal Cancer	Observational	Recruiting	2025-01	China
Clinical Classification of MAFLD Based Liver Biopsy NCT06795646 · ClinicalTrials.gov ↗ · Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)	Observational	Not yet open	2025-02	China
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement NCT06131489 · ClinicalTrials.gov ↗ · Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection	Observational	Not yet open	2023-12	China
Prognostic Model for MASLD Related Cirrhosis NCT07082751 · ClinicalTrials.gov ↗ · Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis	Observational	Not yet open	2025-08	China
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity NCT07135141 · ClinicalTrials.gov ↗ · Severe Obesity	Not applicable	Not yet open	2025-09	China
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections NCT05988177 · ClinicalTrials.gov ↗ · Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses	Not applicable	Not yet open	2023-08	China
HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B NCT07780357 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Not yet open	2026-08	China
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests NCT07087041 · ClinicalTrials.gov ↗ · Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Observational	Not yet open	2025-07	China
DeepMedFake-Assisted Detection of Synthetic and Discordant Medical Images NCT07823023 · ClinicalTrials.gov ↗ · Medical Image Integrity Verification	Not applicable	Not yet open	2026-09	China
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis NCT06773221 · ClinicalTrials.gov ↗ · Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis Drug: Chiglitazar	Not applicable	Not yet open	2025-02	China
A Study on Factors of Biochemical Response in Autoimmune Hepatitis NCT06356506 · ClinicalTrials.gov ↗ · Autoimmune Hepatitis	Observational	Not yet open	2024-05	China
Real-World Data Linkage Research Platform NCT07635355 · ClinicalTrials.gov ↗ · Chronic Diseases, Sub-optimal Health	Observational	Not yet open	2026-05	China
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer NCT07397442 · ClinicalTrials.gov ↗ · Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Not yet open	2026-03	China
Greater China Metabolic and Bariatric Surgery Database NCT03800160 · ClinicalTrials.gov ↗ · Metabolic Surgery	Observational	By invitation	2018-04	China
Disposable Intestinal Isolation and Protection Device for Patients With Rectal and Lower Sigmoid Colon Tumors Undergoing Laparoscopic AR/LAR Surgery NCT07825129 · ClinicalTrials.gov ↗ · Disposable Intestinal Isolation and Protection Device	Not applicable	By invitation	2026-05	China
Data Mining of Population Health-sub-health-disease Based on Dynamic System Theory NCT07375303 · ClinicalTrials.gov ↗ · Sub-healthy	Observational	Active, closed	2025-09	China
Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury NCT06547229 · ClinicalTrials.gov ↗ · Recurrent Drug-induced Liver Injury	Observational	Active, closed	2024-07	China
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer NCT06056804 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer Drugs: Capecitabine, Thymalfasin, Tislelizumab	Phase 2	Active, closed	2024-01	China
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients NCT03777969 · ClinicalTrials.gov ↗ · Chronic Hepatitis b	Observational	Active, closed	2018-06	China
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation NCT06855758 · ClinicalTrials.gov ↗ · Kidney Transplant, Delayed Graft Function, Intraoperative Hypotension Drug: Terlipressin	Not applicable	Active, closed	2025-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Beijing Friendship Hospital trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Tislelizumab3 Golidocitinib2 Thymalfasin2 ACEI/ARB1 Adebrelimab1 Apatinib1 Capecitabine1 Chiglitazar1 Iparomlimab and Tuvonralimab1 Regorafenib1 Sacubitril/valsartan1 Selinexor1 Terlipressin1

Conditions in Beijing Friendship Hospital trials

105 conditions

Hypertension3 Early Gastric Cancer2Metabolic Surgery2Non-Alcoholic Fatty Liver Disease2 Metabolic Dysfunction Associated Steatotic Liver Disease2 Cardiovascular Diseases2 Gastric Cancer (GC)2 Locally Advanced Rectal Cancer2 Rectal Cancer2Metabolic Dysfunction-associated Steatohepatitis (MASH)1Hemophagocytic Lymphohistiocytosis1Epstein-Barr Virus1Bowel Resection1Compensated Cirrhosis1Percutaneous Coronary Intervention1 Gastroesophageal Junction Cancer1 Advanced Gastric Cancer1Metastatic Gastric Cancer1Papillary Thyroid Carcinoma1Thermal Ablation1Adebrelimab1Adenocarcinoma of GE Junction1Adenocarcinoma of Stomach1Severe Obesity1

By trial register

Register	Trials	Recruiting
Clinical trials in China	64	45

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Hypertension

Sponsor	Trials
ReCor Medical	6
Medtronic Vascular	5
Peking University	5
China National Center for Cardiovascular Diseases	5
Shanghai Jiao Tong University School of Medicine	3
Shanghai 10th People's Hospital	3
Jing Liu	3
Aktiia	2
First Hospital of China Medical University	2
Qifu Li	2

Sponsors with the most current trials registered for this condition.

Questions about Beijing Friendship Hospital trials

How many clinical trials does Beijing Friendship Hospital sponsor?

Beijing Friendship Hospital is the lead sponsor of 64 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beijing Friendship Hospital trials recruiting?

Yes. 45 of its 64 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Beijing Friendship Hospital testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Tislelizumab (3), Golidocitinib (2), Thymalfasin (2), ACEI/ARB (1) and Adebrelimab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Beijing Friendship Hospital clinical trials